Eton Pharmaceuticals Inc
Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for N-acetylglutamate synthase deficiency; Beta… Read more
Eton Pharmaceuticals Inc (ETON) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: 0.520x
Based on the latest financial reports, Eton Pharmaceuticals Inc (ETON) has a cash flow conversion efficiency ratio of 0.520x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($12.03 Million) by net assets ($23.13 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Eton Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (2017–2024)
This chart illustrates how Eton Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Eton Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Eton Pharmaceuticals Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Granite Ridge Resources Inc
NYSE:GRNT
|
0.121x |
|
Thomasville Bancshares Inc
PINK:THVB
|
0.055x |
|
PRESS KOGYO CO. LTD
F:2YO
|
N/A |
|
uPI Semiconductor Corp
TW:6719
|
0.020x |
|
Solvac S.A.
BR:SOLV
|
-0.001x |
|
Hoang Huy Investment Financial
VN:TCH
|
0.067x |
|
LYDIA HOLDING A.S.
IS:LYDHO
|
0.021x |
|
Jinling Pharmaceutical Co Ltd
SHE:000919
|
0.015x |
Annual Cash Flow Conversion Efficiency for Eton Pharmaceuticals Inc (2017–2024)
The table below shows the annual cash flow conversion efficiency of Eton Pharmaceuticals Inc from 2017 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $24.43 Million | $969.00K | 0.040x | -90.99% |
| 2023-12-31 | $15.48 Million | $6.82 Million | 0.440x | +19.45% |
| 2022-12-31 | $13.08 Million | $4.82 Million | 0.369x | +237.66% |
| 2021-12-31 | $17.63 Million | $-4.72 Million | -0.268x | +81.23% |
| 2020-12-31 | $15.66 Million | $-22.35 Million | -1.427x | +16.50% |
| 2019-12-31 | $10.55 Million | $-18.03 Million | -1.709x | -451.77% |
| 2018-12-31 | $26.30 Million | $-8.14 Million | -0.310x | +20.39% |
| 2017-12-31 | $12.13 Million | $-4.72 Million | -0.389x | -- |